[go: up one dir, main page]

WO2010119300A9 - Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone - Google Patents

Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone Download PDF

Info

Publication number
WO2010119300A9
WO2010119300A9 PCT/GR2010/000018 GR2010000018W WO2010119300A9 WO 2010119300 A9 WO2010119300 A9 WO 2010119300A9 GR 2010000018 W GR2010000018 W GR 2010000018W WO 2010119300 A9 WO2010119300 A9 WO 2010119300A9
Authority
WO
WIPO (PCT)
Prior art keywords
dexamethasone
aqueous
acetate
vehicle
taste masking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GR2010/000018
Other languages
English (en)
Other versions
WO2010119300A2 (fr
WO2010119300A3 (fr
Inventor
Angelos Kassotakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CASSO PHARMACEUTICALS Ltd
Original Assignee
CASSO PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CASSO PHARMACEUTICALS Ltd filed Critical CASSO PHARMACEUTICALS Ltd
Priority to EP10719774A priority Critical patent/EP2477604A2/fr
Publication of WO2010119300A2 publication Critical patent/WO2010119300A2/fr
Publication of WO2010119300A3 publication Critical patent/WO2010119300A3/fr
Publication of WO2010119300A9 publication Critical patent/WO2010119300A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition pharmaceutiquement acceptable sous la forme d'une suspension d'acétate de dexaméthasone destinée à être administrée par voie orale. Dans ladite composition, le principe actif est dispersé de manière homogène dans un excipient-véhicule pharmaceutiquement acceptable. Cette invention concerne un procédé destiné à masquer le mauvais goût de la dexaméthasone, et une composition pharmaceutique comprenant un ester spécifique de dexaméthasone (acétate de dexaméthasone), en une quantité thérapeutiquement efficace dans un véhicule aqueux stable et compatible, et un agent de mise en suspension. La formulation selon l'invention comprend un acétate de dexaméthasone dispersé dans un véhicule aqueux compatible, à raison d'environ 0,4 à environ 40 mg/ml, de préférence, de 0,4 et environ 10 mg/ml, de préférence encore, de 4 mg/ml. Le véhicule aqueux peut, en outre, être constitué par du glycérol et du propylène glycol. La composition selon l'invention comprend plus d'un excipient pharmaceutique.
PCT/GR2010/000018 2009-04-14 2010-04-14 Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone Ceased WO2010119300A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10719774A EP2477604A2 (fr) 2009-04-14 2010-04-14 Suspension d'acétate de dexaméthasone à usage oral composition masquant le goût de la dexaméthasone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20090100230A GR20090100230A (el) 2009-04-14 2009-04-14 Απο του στοματος εναιωρημα οξικης δεξαμεθανοζης-συνθεση καλυψης γευσης της δεξαμεθανοζης
GR20090100230 2009-04-14

Publications (3)

Publication Number Publication Date
WO2010119300A2 WO2010119300A2 (fr) 2010-10-21
WO2010119300A3 WO2010119300A3 (fr) 2011-03-24
WO2010119300A9 true WO2010119300A9 (fr) 2011-07-28

Family

ID=42269791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GR2010/000018 Ceased WO2010119300A2 (fr) 2009-04-14 2010-04-14 Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone

Country Status (3)

Country Link
EP (1) EP2477604A2 (fr)
GR (1) GR20090100230A (fr)
WO (1) WO2010119300A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
WO2013149258A2 (fr) 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions et procédés de traitement ou de prévention de troubles du syndrome métabolique
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2159195A1 (en) 1971-11-10 1973-06-22 Fabre Sa Pierre Compsns contg sorbitol and a corticoid or pyrazolone - - suppression of ulcerogenic effects
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
MXPA06012088A (es) 2004-04-22 2007-08-14 Duocort Ab Composiciones farmaceuticas para terapia aguda con glucocorticoides.
LT2377557T (lt) 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
NZ555641A (en) 2004-12-09 2010-10-29 Bayer Animal Health Gmbh Stabilisation of glucocorticoid esters with acids
DE102005055385A1 (de) 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
US8468589B2 (en) 2006-01-13 2013-06-18 Fortinet, Inc. Computerized system and method for advanced network content processing
ES2327775T3 (es) 2005-12-09 2009-11-03 Teva Pharmaceutical Industries, Ltd. Dispersiones y soluciones acuosas de compuestos dificiles de disolver y procedimientos para su preparacion.
CN101190177B (zh) * 2006-11-24 2010-09-01 上海医药工业研究院 醋酸地塞米松局部成膜凝胶组合物及其应用

Also Published As

Publication number Publication date
WO2010119300A2 (fr) 2010-10-21
EP2477604A2 (fr) 2012-07-25
GR20090100230A (el) 2010-11-18
WO2010119300A3 (fr) 2011-03-24

Similar Documents

Publication Publication Date Title
WO2023114943A3 (fr) Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques
WO2019036008A8 (fr) Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
WO2008019996A3 (fr) Formulations de flibansérine et leur procédé de fabrication
WO2012079092A3 (fr) Compositions d'undécanoate de testostérone
EP2246049A3 (fr) Compositions pharmaceutiques et formes posologiques pour l'administration de médicaments hydrophobes
MX2010003923A (es) Formulacion farmaceutica de valsartan.
WO2009095681A3 (fr) Formulations pour suspensions
WO2010032140A3 (fr) Préparations pharmaceutiques et méthodes associées d'administration
MX2014013998A (es) Composiciones antimucosidad a base de xilitol y metodos y composiciones.
WO2012054831A3 (fr) Formulations de kétorolac prêtes à l'emploi
WO2005105067A3 (fr) Administration de medicaments au fond de l'oeil
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
JP2011516425A5 (fr)
WO2010015665A3 (fr) Composés et procédés
WO2007093425A3 (fr) Forme d'administration par voie orale stable au stockage d'amoxicilline et d'acide clavulanique
JP2014530801A5 (fr)
WO2009090670A3 (fr) Composition à libération prolongée stabilisée à base de chlorhydrate de bupropion et procédé de préparation de cette composition
WO2012021107A3 (fr) Formulation de liposomes pour l'administration d'un médicament dans l'œil
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
WO2008023016A3 (fr) Formulations galéniques de composés organiques
WO2007022255A3 (fr) Preparations pharmaceutiques a liberation prolongee
MY160652A (en) Pharmaceutical composition for oral administration
EP2279732A3 (fr) Composés et compositions pour la distribution d'agents actifs
AU2010293105A8 (en) Oral suspension formulations of esclicarbazepine acetate
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719774

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010719774

Country of ref document: EP